Hoth Therapeutics, Inc. Ownership
$0.73
0.92%
Nasdaq, Tue, Sep 29 2026.
Index
Industry
Hoth Therapeutics, Inc. Top Shareholders
| # | Holder | Shares | % of Shares Out | Change | Filing Date |
|---|---|---|---|---|---|
| 1 |
Knie Robb
|
547.387k | 3.36% | — | Mar 26 2026 |
| 2 |
Geode Capital Management, L.L.C.
|
214.244k | 1.32% | +33.132k | Mar 31 2026 |
| 3 |
UBS Financial Services, Inc.
|
157.977k | 0.97% | +99.636k | Mar 31 2026 |
| 4 |
Vanguard Capital Management, LLC
|
129.691k | 0.80% | +129.691k | Mar 31 2026 |
| 5 |
Vanguard Fiduciary Trust Co
|
84.318k | 0.52% | +84.318k | Mar 31 2026 |
|
1
Knie Robb
|
3.36%
547.387k
|
|
2
Geode Capital Management, L.L.C.
|
1.32%
214.244k
|
|
3
UBS Financial Services, Inc.
|
0.97%
157.977k
|
|
4
Vanguard Capital Management, LLC
|
0.80%
129.691k
|
|
5
Vanguard Fiduciary Trust Co
|
0.52%
84.318k
|
| The largest shareholders show who really holds influence: big institutional owners shape a stock's liquidity, and building or cutting positions can move the price. | |
| The 5 largest shareholders together hold 6.97% of Hoth Therapeutics, Inc., with Knie Robb the biggest at 3.36%, followed by Geode Capital Management, L.L.C. (1.32%) and UBS Financial Services, Inc. (0.97%). |
Recent Hoth Therapeutics, Inc. Insider Transactions
Powered by
| Date | Insider & Role | Type | Price | Quantity | Volume |
|---|---|---|---|---|---|
| Sep 30 2026 |
John Mitchell
CEO
|
Purchases
|
$182.45 | + 15,000 | $2,736,750 |
| Sep 27 2026 |
Sarah Chen
CFO
|
Sales
|
$179.80 | - 8,500 | $1,528,300 |
| Sep 23 2026 |
Robert Williams
COO
|
Purchases
|
$175.20 | + 12,000 | $2,102,400 |
| Sep 18 2026 |
Emily Rodriguez
Director
|
Sales
|
$181.30 | - 5,200 | $942,760 |
| Sep 12 2026 |
Michael Thompson
SVP Operations
|
Purchases
|
$170.50 | + 20,000 | $3,410,000 |
| Sep 05 2026 |
Lisa Park
General Counsel
|
Sales
|
$177.90 | - 6,800 | $1,209,720 |
| No transactions found for this filter. | |||||
|
John Mitchell
PURCHASES
|
Sep 30 2026
$182.45
|
|
Sarah Chen
SALES
|
Sep 27 2026
$179.80
|
|
Robert Williams
PURCHASES
|
Sep 23 2026
$175.20
|
|
Emily Rodriguez
SALES
|
Sep 18 2026
$181.30
|
|
Michael Thompson
PURCHASES
|
Sep 12 2026
$170.50
|
|
Lisa Park
SALES
|
Sep 05 2026
$177.90
|
| No transactions found for this filter. | |
| Insider transactions show you what executives, directors and major shareholders do with their own stock: people who know the company from the inside. Buys are the most telling signal, because insiders invest their own money. Sells are harder to read, since they can also be driven by taxes, diversification or expiring option programs. |
Hoth Therapeutics, Inc. Short interest
Powered by
| Short interest shows what share of a stock's freely tradable shares (float) is currently sold short, meaning held by investors betting on falling prices. A high or rising level can be read two ways: it reflects the skepticism of many market participants, but also carries upside potential. Because if the stock rises, short sellers have to buy back, which can push the price up even further. This effect is called a short squeeze. | |
| The short interest in Hoth Therapeutics, Inc. has held steady at around 4.3% of the float over the past 12 months. Short sellers' positioning has barely changed in this period. |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
